ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Aadi Bioscience, Inc. (AADI) stock remained unchanged at $1.93 a share on NASDAQ. The stock opened at $1.94, fluctuating between $1.85 to $1.96 during the session.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Employees | 53 |
Beta | 0.34 |
Sales or Revenue | $24.35M |
5Y Sales Change% | -0.898% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |